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Background: Cognitive impairment is common in patients with cerebral small vessel disease, but is not well
detected using common cognitive screening tests which have been primarily devised for cortical dementias. We
developed the Brief Memory and Executive Test (BMET); a rapid screening measure sensitive to the impaired
executive function and processing speed characteristic of small vessel disease (SVD). To assess the BMET’s validity
for general use, we evaluated it when administered by non-psychologists in a multicentre study and collected
control data to derive normative scores.
Methods: Two-hundred participants with SVD, defined as a clinical lacunar stroke and a corresponding lacunar
infarct on MRI, and 303 healthy controls aged between 40–90 years old were recruited. The BMET, as well as the
Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE), were performed. Overall, 55
SVD participants underwent repeat testing at 3 months to assess the BMET test-retest reliability.
Results: Administering the BMET took a mean (SD) of 12.9 (4.7) in cases and 9.5 (2.6) minutes in controls. Receiver
Operator Curve analysis showed the BMET was a good predictor of cognitive impairment in SVD (AUC = 0.94) and
performed significantly better than both the MoCA (AUC = 0.77) and the MMSE (AUC = 0.70). Using a cut-off score
of 13, the BMET had a sensitivity of 93% and specificity of 76% for detecting cognitive impairment in SVD.
Conclusions: The BMET is a brief and sensitive tool for the detection of cognitive impairment in patients with SVD.
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Cerebral small vessel disease (SVD), which causes lacu-
nar stroke accounting for 10 to 30% of all ischemic
strokes, is the major cause of vascular cognitive impair-
ment (VCI) and vascular dementia [1]. VCI due to SVD is
associated with a characteristic profile of impairment in
cognitive flexibility, attention, and processing speed with a
relatively spared performance on memory tasks [2]. Cog-
nitive impairment (CI) in patients presenting with lacunar
stroke or other manifestations of SVD is common [3], with
up to 50% of patients with lacunar stroke having some de-
gree of cognitive impairment, which predicts subsequent
progression to vascular dementia [4,5], and has been* Correspondence: mjh249@medschl.cam.ac.uk
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unless otherwise stated.shown to have a major impact on quality of life [6]. How-
ever, despite this, VCI associated with SVD is often missed
in a clinical setting.
A key contributing factor to under diagnosis is the
current use of cognitive screening measures, such as the
Mini Mental State Examination (MMSE) [7], that have
been developed primarily for the assessment of cortical
dementias such as Alzheimer’s Disease and have been
shown to be insensitive to the cognitive deficits found in
patients with VCI due to SVD [8]. The lack of a widely
available validated screening tests for this group has
been recognised in the National Institute of Neurological
Disorders and Stroke-Canadian Stroke Network Vascular
Cognitive Impairment Harmonization Standards [9], which
proposed specific cognitive protocols, but these take a
minimum of 20 to 60 minutes to complete. The Brief
Memory and Executive Test (BMET) [10] was designed tol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which would be suitable for use by health professionals in
in- and out-patient settings. It is primarily for screening
VCI in patients with SVD, helping differentiate such deficits
from those found in patients with cortical dementias; it in-
corporates specifically adapted measures of executive func-
tioning and processing speed, designed to be brief but
sensitive, combined with measures of memory functioning.
In a preliminary study, the BMET accurately differentiated
VCI due to SVD from CI due to Alzheimer’s disease, with a
sensitivity of 91% and specificity of 85% [10].
We performed a comprehensive validation of the previ-
ously developed BMET [10], evaluating it in 19 stroke cen-
tres throughout England, with administration of the BMET
by doctors and research nurses rather than neuropsycholo-
gists. We also recruited a large control sample to standard-
ise the test and compared the performance of the BMET
against the Montreal Cognitive Assessment (MoCA [11])
and the Mini Mental State Examination (MMSE [7]), two
measures frequently used as brief cognitive screening tools
in stroke patients, including patients with SVD.
Methods
This study was approved by the London Bridge Research
Ethics Committee (11/LO/0636) and all participants
gave informed consent before taking part in this study.
Participants
Two-hundred participants with lacunar stroke were re-
cruited from 19 sites across the English Stroke Research
Network (see below for a list of sites). In order to match
SVD patients with controls, we included all participants
aged between 40 and 90 years of age (n = 196), who were
fluent in English. All participants were tested >3 months
post-stroke to exclude any acute effects of stroke on
cognitive performance. The sample size was calculated
based on a meta-analysis examining studies looking at
the relationship between leukoaraiosis and cognitive per-
formance [12], which found modest correlations of r =
0.2 to 0.3. Taking the mid-point (r = 0.25), we calculated
that a sample of 200 would produce acceptable signifi-
cance levels for a range of analyses, including those cor-
recting for multiple comparisons using conservative
measures such as a Bonferroni correction. All patients
included in the study presented with a clinical lacunar
syndrome (e.g., hemiparesis, hemisensory deficit, sen-
sorimotor deficit, ataxic hemiparesis, or clumsy hand
dysarthria) or partial lacunar syndrome (e.g., pure motor
stroke affecting face and arm or arm and leg) with an
MRI confirmed lacunar infarct in an anatomically corre-
sponding location. Lacunar infarction was defined as a
subcortical infarct ≤1.5 cm in diameter, on MRI.
For all cases, MRI scans were centrally reviewed to con-
firm eligibility and to grade the degree of leukoaraiosisusing the Fazekas’ scale [13]. Exclusion criteria were as fol-
lows: i) stenosis >50% in the extracranial or intracranial
cerebral vessels, or previous carotid endarterectomy, ii)
cardioembolic source of stroke, defined according to the
TOAST criteria as high or moderate probability, and/or
iii) the presence of a cortical infarct >1 cm diameter on
MRI. SVD patients were included if they had either iso-
lated lacunar infarcts (n = 122) or lacunar infarcts with
leukoaraiosis (Fazekas grade ≥2, n = 74), the lacunar in-
farcts occurring for the first time or recurrently.
Overall, 303 healthy controls were recruited from local
family doctors practices or other volunteer groups. Indi-
viduals with cardiovascular risk factors and other comor-
bidities were included, but individuals with a past
history of stroke, transient ischemic attack, and major
central neurological or major psychiatric disease were
excluded. Controls were recruited in stratified age bands
to provide a representative sample. In order to establish
the test-retest reliability of the BMET, 55 of the SVD pa-
tients and 105 controls were retested after 3 months.
Measures
The Brief Memory and Executive Test (BMET) incorpo-
rates tests divided into two main categories: i) executive
functioning and processing speed which includes letter-
number matching, motor-sequencing, letter-sequencing,
and number-letter sequencing; and ii) orientation and
memory which includes orientation, five-item repetition,
five-item recall, and five-item recognition memory. Full
descriptions of each task are presented in the supple-
mentary materials (see Additional file 1). Two versions
of the BMET were created, one for right-handed and an-
other for left-handed patients. The difference here is that
that the sequencing measures were mirrored to reduce
covering of the letters/numbers during test completion.
The BMET is available to download from the Cambridge
University Stroke Research Group [14].
In addition, we collected data for a range of descriptive
variables and background or comparative standardized
measures, including the National Adult Reading Test
(NART) [15], which is a commonly used and validated
measure of pre-morbid intellectual ability, MMSE [7]
and MoCA [11] (see Table 1 for descriptive statistics).
Statistical analysis
Differences between the two main groups on descriptive
variables, the BMET raw scores, and other cognitive tests
were explored using t-tests and χ2 tests. Normative data
from the control sample was then used to establish age-
scaled scores for each of the BMET tests. To do this, the
control sample was divided into seven age groups: 40–49
(n = 72), 50–59 (n = 71), 60–69 (n = 49), 70–74 (n = 30),
75–79 (n = 37), 80–84 (n = 36), and 85–90 (n = 8). Based
on the mean and standard deviation (SD) for each
Table 1 Descriptive statistics of demographic and clinical







Demographic variables, Mean (SD)
Age 62.5 (13.8) 63.5 (9.9) t = 0.86 (P = 0.38)
Years education 14.0 (2.8) 13.7 (3.8) t = 1.2 (P = 0.22)
Gender (% male) 54% 68%
Socioeconomic status
Professional 13% 11% χ2 = 0.50 (P = 0.47)
Managerial 42% 34% χ2 = 3.9 (P = 0.05)
Skilled 35% 40% χ2 = 1.08 (P = 0.29)
Partly skilled 7% 10% χ2 = 1.25 (P = 0.26)
Unskilled 1% 2% χ2 = 0.95 (P = 0.32)
Other 2% 3% χ2 = 1.2 (P = 0.27)
Risk factors, Mean (SD)
Weight (kg) 74.8 (18.3) 81.6 (15.9) t = 4.3 (P ≤0.001)
Systolic BP (mmHg) 132 (17.7) 139.7 (17.9) t = 4.4 (P ≤0.001)
Diastolic BP (mmHg) 78.9 (10.7) 80.6 (10.5) t = 1.6 (P = 0.102)
Units of alcohol per week 11.6 (13.1) 8.54 (14.6) t = 1.2 (P = 0.016)
Time since last
stroke (months)
– 20.5 (32.3) –
Treated hypertension 28% 75% χ2 = 103 (P ≤0.001)
Treated hyperlipidaemia 24% 78% χ2 = 143 (P ≤0.001)
Diabetes mellitus (%) 6% 23% χ2 = 30.3 (P ≤0.001)
Smoker (% ever a smoker) 58% 44% χ2 = 19.4 (P ≤0.001)
Cognitive scores
MMSE 28.2 (1.9) 28.04 (2.2) t = 1.1 (P = 0.27)
MoCA 25.6 (3.2) 24.7 (3.3) t = 2.8 (P = 0.005)
MoCA, Montreal Cognitive Assessment; MMSE, Mini Mental State Examination.
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established for the assignment of scores of “1” for those
who scored between 1 or 2 SD’s below the normative
mean and “0” for those who scored 2 SD’s or more below
the normative mean. A score of “2” was assigned to partic-
ipants who scored within 1 SD of the normative mean.
This allowed the generation of an age-scaled total score
(0–16), an executive functioning/processing speed sub-
scale (0–8), and an orienting/memory subscale (0–8). The
internal consistency and test-retest reliability of these
index scores were tested using the Cronbach’s alpha (α)
test and correlations, respectively.
VCI was then defined within the SVD sample using
the pre-defined Petersen Mild Cognitive Impairment
threshold [16] of scoring ≤1.5 SD of the control popula-
tion mean on a given test. We refined this to make it
more conservative by making a classification of VCI
where patients fell below this threshold on at least fourof eight of the BMET tests. This was the same definition
used in the preliminary BMET study [10].
This method stratified the SVD group into those who
did (SVD-CI, n = 26) or did not (SVD-nCI, n = 170) meet
criteria for VCI. Group differences in cognitive perform-
ance between these resulting groups (raw scores) were
compared using a non-parametric Wilcoxon Signed-rank
test due to the unbalanced group sizes (these groups did
not significantly differ on descriptive variables apart from
a trend for SVD-CI to have higher systolic blood pressure
(z = 1.8, P = 0.07)).
Finally, relative sensitivity and specificity of the BMET,
MMSE, and MoCA to identify CI in SVD was explored by
plotting a receiver operating characteristic (ROC) curve for
each measure and comparing the area under the curve
(AUC) for each. AUC is a standard measure of the strength
of a test with a score of 1.0 representing the best discrimin-
ant ability and 0.5 being at chance level. The current ana-
lysis consisted of a logistic regression where the relative
cognitive tests’ total score (i.e., BMET, MoCA, or MMSE)
was regressed onto a dichotomous variable of the presence
or absence of cognitive impairment to establish whether it
was a significant predictor of group status. This was
followed by the plotting of a ROC curve and the generation
of optimal cut-off points for the BMET using the roctab
command in STATA. Finally, the AUCs for each measure
were compared using the roccomp command.
In order to ensure that we did not inadvertently inflate
the AUC of the BMET by defining CI using this test alone,
we performed a secondary analysis using a more stringent
cut-off for VCI diagnosis. This categorised patients as hav-
ing VCI if they scored ≤1.5 SD of the control population
mean on any four of the BMET subtests, and in addition
met the MoCA cut-off for CI (<26, n = 20).
All analyses were conducted in STATA 13 [17].
Results
Descriptive statistics
The SVD and control groups did not differ significantly
in age, years of education, or IQ (NART), and were
closely matched on socioeconomic status. Demograph-
ics of both groups are shown in Table 1. Review of the
MRI scans revealed that 59% of the SVD patients had
isolated lacunar infarcts without leukoaraiosis, 37.5%
had multiple lacunar infarcts and confluent leukoaraio-
sis, and 3.5% had multiple lacunar infarcts without leu-
koaraiosis. On Fazekas scale grading 38% scored ≥2,
15% scored 1, and 47% scored 0. Missing data for key
variables were as follows: height/weight, SVD = 1, con-
trol = 6; blood pressure, SVD = 11, control = 0.
Cognition on MOCA and MMSE
The SVD group performed worse than controls on the
MoCA (SVD, mean = 24.7, SD = 3.3; control, mean =
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the groups did not differ on the MMSE (SVD, mean =
28.04, SD = 2.2; control, mean = 28.2, SD = 1.9, P = 0.27).
BMET Performance
The mean (SD) time taken to administer the BMET was
12.9 (4.7) minutes in SVD cases and 9.5 (2.6) minutes in
controls.
The SVD group performed worse than the controls on all
BMET raw scores except orientation (Independent t-tests,
see Table 2); this subtest was included to help discriminate
SVD from early Alzheimer’s disease [10]. Table 3 shows
the age-scaled test scores and indices based on control
group data, and shows the SVD-CI group scoring signifi-
cantly lower on total performance, the executive/process-
ing speed index, the orientation/memory index scores,
and all of the individual subtests when compared to the
SVD-nCI group.
Internal consistency and test-retest reliability of
the BMET
Internal consistency was found to be adequate for total
performance (whole sample, α = 0.82; SVD, α = 0.69;
control, α = 0.61) and the executive functioning/pro-
cessing speed index (whole sample, α = 0.78; SVD, α =
0.72; control, α = 0.60), while the internal consistency for
the orientation/memory index was considerably lower
(whole sample, α = 0.68; SVD, α = 0.35; control, α = 0.45).
Test-retest reliability in the SVD subgroup (n = 54) over a
3 month period was also found to be adequate for total
performance (r = 0.69, P ≤0.001), executive functioning/
processing speed (r = 0.68, P ≤0.001), and orientation/mem-
ory (r = 0.40, P ≤0.001). Similar results were found for the
control group for total performance (r = 0.47, P ≤0.001), ex-
ecutive functioning/processing speed (r = 0.61, P ≤0.001),
and orientation/memory (r = 0.40, P ≤0.001).Table 2 Group differences in performance on the Brief Memo
Control
Time taken (minutes) 9.5 (2.6)
Executive functioning and processing speed
Letter-number matching (0–40) 27.7 (7.0)
Motor sequencing (s) 10.7 (8.0)
Letter sequencing (s) 36.8 (24.7)
N-L sequencing (s) 49.2 (43.3)
Orientation and memory
Orientation (0–10) 9.90 (0.3)
Five item repetition (0–15) 14.5 (1.1)
Five item recall (max 5) 3.7 (1.4)
Five item recognition (max 5) 4.2 (1.0)ROC analysis of the BMET and comparison with the MoCA
and MMSE
Using our predefined criteria (see Methods), approximately
13% of participants with SVD had VCI. We calculated the
sensitivity and specificity of the BMET, MoCA, and MMSE
to VCI, and then plotted ROC curves for each measure.
The BMET total performance index was a significant
predictor of group status (β = 0.79, odds ratio (OR) =
2.22, P ≤0.001), with the ROC analysis indicating an
AUC of 0.94 (95% confidence interval (CI) = 0.89–0.99).
From the ROC curve, an optimal BMET total cut-off
score of “13” was identified, which identified VCI in
SVD with 93% sensitivity and 76% specificity, correctly
classifying 78% of patients. Additional file 2 provides a
table containing the sensitivity and specificity for alterna-
tive BMET cut-off ’s and their comparison with MoCA and
MMSE equivalents. A comparison with MoCA and
MMSE showed that, although both tests did significantly
predict group status (MoCA β = 0.29, OR = 1.34, P ≤0.001,
MMSE β = 0.30, OR = 1.36, P ≤0.001), the BMET pro-
vided better discrimination (MoCA AUC = 0.77, 95%
CI = 0.67–0.87; BMET vs. MoCA χ2 = 13.96, P ≤0.001;
MMSE AUC = 0.70, 95% CI = 0.59–0.81; BMET vs.
MMSE χ2 = 20.9, P ≤0.001; Figure 1). The MoCA and
MMSE did not significantly differ between each other in
their discriminative ability (χ2 = 1.6, P = 0.20). Post-hoc
analysis comparing the AUCs of the BMET, MoCA, and
MMSE when defining cognitive impairment using more
stringent criteria (see Methods) resulted in similar re-
sults (BMET AUC = 0.95, 95% CI = 0.91–0.99, MoCA
AUC = 0.89, 95% CI = 0.83–0.94, MMSE AUC = 0.75,
95% CI = 0.67–0.86).
Discussion
Building on our previous study demonstrating the effect-
iveness of the BMET in differentiating patients withry and Executive Test sub-scale raw scores (mean, SD)
SVD t-test
12.9 (4.7) t = 10.3 (P ≤0.001)
24.1 (7.7) t = 5.3 (P ≤0.001)
21.4 (22.1) t = 7.2 (P ≤0.001)
56.1 (39.6) t = 6.7 (P ≤0.001)
73.0 (57.3) t = 5.3 (P ≤0.001)
9.87 (0.4) t = 0.73 (P = 0.46)
13.8 (1.9) t = 5.1 (P ≤0.001)
3.04 (1.7) t = 5.8 (P ≤0.001)
3.7 (1.6) t = 5.1 (P ≤0.001)
Table 3 Brief Memory and Executive Test (BMET) normalised individual, total performance, and index scores for the
whole Small Vessel Disease (SVD) group and for those with and without cognitive impairment
SVD (whole sample) SVD-nCI (n = 170) SVD-CI (n = 26) SCD-nCI vs. SVD-CI
Executive functioning and processing speed
Letter-number matching 1.7 (0.6) 1.8 (0.5) 1.1 (0.7) z = 5.9 (P ≤0.001), r = 0.42
Motor sequencing 1.7 (0.7) 1.8 (0.6) 1.1 (0.9) z = 4.6 (P ≤0.001), r = 0.33
Letter sequencing 1.7 (0.7) 1.9 (0.5) 0.6 (0.8) z = 8.7 (P ≤0.001), r = 0.62
N-L sequencing 1.8 (0.6) 1.9 (0.4) 0.9 (0.8) z = 7.9 (P ≤0.001), r = 0.56
Orientation and Memory
Orientation 1.9 (0.4) 1.9 (0.4) 1.7 (0.6) z = 2.3 (P = 0.02), r = 0.16
Five item repetition 1.5 (0.8) 1.7 (0.7) 0.6 (0.9) z = 5.8 (P ≤0.001), r = 0.41
Five item recall 1.7 (0.7) 1.8 (0.6) 1.2 (0.9) z = 3.7 (P ≤0.001), r = 0.25
Five item recognition 1.7 (0.7) 1.8 (0.6) 1.4 (0.9) z = 2.4 (P = 0.02), r = 0.17
Composite total score and sub-scales
BMET Total 13.6 (2.9) 14.4 (1.9) 8.7 (2.8) z = 7.4 (P ≤0.001), r = 0.53
BMET EF/PS 6.9 (1.8) 7.3 (1.2) 3.8 (2.1) z = 7.9 (P ≤0.001), r = 0.56
BMET Orient/Mem 6.7 (1.6) 7.1 (1.3) 4.9 (1.9) z = 5.6 (P ≤0.001), r = 0.40
SVD-nCI, SVD with no cognitive impairment; SVD-CI, SVD with cognitive impairment.
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multicentre evaluation established that the BMET,
when administered by non-psychologists, showed good
sensitivity and specificity in the detection of CI in pa-
tients with SVD. It showed significantly better per-
formance in detecting VCI than either of the two
measures commonly used in current clinical practice,
the MMSE and the MOCA. The BMET was reliablyFigure 1 Comparison of ROC analysis of the Brief Memory and Execu
Examination tests of cognitive impairment.administered by non-psychologists in a mean time of
13 minutes in the SVD group, making it appropriate
for use as a brief screening measure. We collected data
allowing construction of population norms which will
be useful for implementation of the BMET. Using
these, we established an optimal clinical cut-off of 13,
at which the BMET showed a high sensitivity (93%)
and specificity (76%) for detecting VCI.tive Test, Montreal Cognitive Assessment, and Mini Mental State
Brookes et al. BMC Medicine  (2015) 13:51 Page 6 of 8This paper demonstrates the sensitivity of the BMET
as a tool to screen for VCI in people with SVD, and pro-
vides age-normed scaled scores based on a large sample
of healthy older adults selected from across the UK. It
should be noted that while we compared the BMET to
the MoCA and MMSE, there are other tests already
available that may have a greater focus of executive func-
tioning. For instance, the CAMCOG [18] includes more
measures of executive functioning, but may be too long
and cover too many domains of functioning to be a use-
ful screening test in SVD. The INCEO Frontal Screening
[19], which although perhaps more useful, does not
include the tests which have been shown to me most
sensitive to SVD such as the trail-making task or digit-
symbol coding [8]. Nevertheless, it would be useful to
demonstrate empirically the relative strengths and weak-
nesses of each of these measures versus the BMET.
The better performance of the BMET compared with
the MMSE and MoCA is due to its specific development
for this purpose, in contrast with the existing tests which
have been developed to detect cortical dementias such
as Alzheimer’s disease. In contrast, the BMET focuses
on cognitive difficulties that are more prominent in SVD
and sub-cortical VCI, namely executive functioning and
processing speed [20,21]. While the need for such a
measure has been recognised for some time [9], most
previously suggested protocols, while sensitive, take too
long to administer [8,9] to be useful as a brief assess-
ment in the acute or out-patient clinic settings. Further-
more, by also including tests of orientation and memory,
the BMET has the scope to differentiate between SVD
with CI and early Alzheimer’s disease, as was shown in
our preliminary study [10]. In addition to the BMET’s clin-
ical utility, it also shows promise for use in research stud-
ies in which brief measures attuned to the cognitive
profile of SVD are needed. Given that we have shown that
the BMET has good test-retest reliability, applications
could include the use of the BMET in large epidemio-
logical studies or clinical trials which require a large num-
ber of patients to have cognitive testing. In the latter,
parallel versions are likely to be necessary to reduce learn-
ing effects. The importance of using cognitive tests sensi-
tive to the deficit seen in patients with SVD to detect
treatment effects in clinical trials has been previously doc-
umented [22]. Furthermore, it is particularly important for
sensitive neuropsychological screening tools to be imple-
mented in trials involving first-ever lacunar stroke patients
who may have subtle cognitive difficulties which may pre-
dict latter VCI [5].
Despite evidence that the BMET is a strong predictor of
VCI in SVD, there are a number of study limitations that
should be considered. Firstly, in order to validate the use
of the BMET in a wide range of SVD patients, we included
the full range of patients with lacunar stroke from thosewith isolated lacunar infarcts to multiple lacunar infarcts
and from no to severe leukoaraiosis. SVD is a heteroge-
neous disease and future research should show that the re-
sults presented here are generalizable across all its clinical
presentations. It has also been suggested that CI is more
common in those who have multiple lacunar infarcts [23].
Furthermore, while the BMET demonstrated good in-
ternal consistency for the total score and the executive
functioning/processing speed subscale, this was substan-
tially lower for the orientation/memory subscale in the
SVD group. We suggest that the reason for this is the rela-
tive sparing of orientation ability compared to executive
functioning/processing speed in those with SVD. Given
that this subscale is primarily intended to aid in the differ-
entiation between SVD and Alzheimer’s disease [10], fu-
ture research is required to investigate the psychometric
properties of this subscale in that patient group.
Despite having a relatively large sample size of healthy
controls, dividing our sample into age-ranges for the de-
velopment of scaled scores significantly reduced our in-
dividual cell size in the older age ranges (e.g., 85–90),
possibly making the scaled scores less reliable. More re-
search focusing on recruiting a larger and more represen-
tative sample of those aged >80 years of age will be
required. We plan to continue to build our normative
sample for the BMET allowing us to refine the scales and
conduct additional analyses, including the stratification
groups by not only age but also education and gender.
This study would have benefited from a more compre-
hensive evaluation of neuropsychological performance as
an external validator of the presence of cognitive impair-
ment. One future direction would be to assess how accur-
ately the cognitive profile identified by the BMET maps
onto a full neuropsychological assessment both acutely
and in longitudinal studies to see whether the BMET can
be used to predict the later development of VCI. It is im-
portant that sensitive neuropsychological screening tools
are implemented in trials involving first-ever lacunar
stroke patients who may have subtle cognitive difficulties
to allow the determination of whether such deficits predict
the development of vascular dementia [5].
Conclusions
In conclusion, we have demonstrated the utility of the
BMET as a tool to screen for VCI in patients with SVD, a
disease group who make up the majority of cases of CI as-
sociated with cerebrovascular disease and who are poorly
served by current screening tests. We found that the
measure has good sensitivity and specificity and, in this
patient group, outperformed two commonly used brief
cognitive screening tools. Furthermore, the BMET’s short
administration time and good test-retest reliability indi-
cates that it could be effective across a number of clinical
and research settings.
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Additional file 1: Brief memory and executive test subtest
descriptions.
Additional file 2: Age-normed cut-off scores for Brief Memory and
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